2 results
Approved WMOCompleted
To assess the effect of switching CML patients, who have been treated with imatinib *2 years and who have stable detectable molecular residual disease above 0.01% (IS), to the combination of Nilotinib and PegIFN, in terms of the proportion of…
Approved WMOCompleted
To investigate the feasibility of the implementation of a point-of-care immunological test based on blood cells of all trauma patients with the aid of an automated load-and-go flow cytometer in an acute trauma care setting at the shock room.